AiViva Biopharma Completes Patient Enrollment in Phase 1 Trial of AIV007

AiViva Biopharma Completes Patient Enrollment in Phase 1 Trial of AIV007

By, Admin 27 August 2024

AiViva Biopharma completes patient enrollment in phase 1 trial of AIV007 for age-related macular degeneration and diabetic macular edema

Overview

AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a phase 1 trial with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME).  “We have achieved a major milestone, full enrollment in our phase 1, safety trial in the US” said Diane Tang-Liu, PhD, CEO, president & co-founder of AiViva Biopharma.  “AIV007 (lenvatinib) is a broad-spectrum tyrosine kinase inhibitor, targeting the convergence of fibrosis, angiogenesis, and inflammation. We believe AIV007, formulated with our proprietary JEL technology and administered periocularly, has the potential to address the root causes of wet AMD, DME and many other ocular diseases.  We are on target to have the study completed, and full results Q1 2025.

Phase I Trial

This phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial, with 18 subjects, who have received a single periocular injection of AIV007 and will undergo monthly evaluation for up to 6 months to assess safety, tolerability, biological activity, and the reduction of treatment burden.

Age-Related Macular Degeneration

  • AMD is a progressive retinal disease that is the leading cause of blindness in adults over the age of 60, affecting up to 15 million US people. 
  • AMD affects the macular, center portion of the retina, that is responsible for central vision and color perception. 
  • In patients with wet AMD vision loss is caused by abnormal blood vessels leaking fluid and blood into and beneath the retina.

Diabetic Macular Edema

  • Diabetic macular edema is manifested as retinal thickening and swelling caused by accumulation of intraretinal fluid usually due to blood sugar levels being consistently high. 
  • If untreated, chronic macular edema can lead to irreversible damage of the macula and permanent vision loss.

About AiViva

  • AiViva is a clinical stage biotech company led by a team of seasoned industry experts with proven track record in drug development and commercialization. 
  • AiViva has developed innovative approaches to address high unmet medical needs through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!